Ovarian cancer: emerging molecular-targeted therapies

Carole SourbierRockville, MD, USAAbstract: With about 22,000 new cases estimated in 2012 in the US and 15,500 related deaths, ovarian cancer is a heterogeneous and aggressive disease. Even though most of patients are sensitive to chemotherapy treatment following surgery, recurring disease is almost...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Sourbier C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/dd4a34d48c32494997b7bf50af34c666
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dd4a34d48c32494997b7bf50af34c666
record_format	dspace
spelling	oai:doaj.org-article:dd4a34d48c32494997b7bf50af34c6662021-12-02T00:01:10ZOvarian cancer: emerging molecular-targeted therapies1177-54751177-5491https://doaj.org/article/dd4a34d48c32494997b7bf50af34c6662012-06-01T00:00:00Zhttp://www.dovepress.com/ovarian-cancer-emerging-molecular-targeted-therapies-a10178https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Carole SourbierRockville, MD, USAAbstract: With about 22,000 new cases estimated in 2012 in the US and 15,500 related deaths, ovarian cancer is a heterogeneous and aggressive disease. Even though most of patients are sensitive to chemotherapy treatment following surgery, recurring disease is almost always lethal, and only about 30% of the women affected will be cured. Thanks to a better understanding of the molecular mechanisms underlying ovarian cancer malignancy, new therapeutic options with molecular-targeted agents have become available. This review discusses the rationale behind molecular-targeted therapies and examines how newly identified molecular targets may enhance personalized therapies for ovarian cancer patients. Keywords: ovarian cancer, angiogenesis, PI3K/Akt, BRCA, metabolismSourbier CDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2012, Iss default, Pp 147-154 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Sourbier C Ovarian cancer: emerging molecular-targeted therapies
description	Carole SourbierRockville, MD, USAAbstract: With about 22,000 new cases estimated in 2012 in the US and 15,500 related deaths, ovarian cancer is a heterogeneous and aggressive disease. Even though most of patients are sensitive to chemotherapy treatment following surgery, recurring disease is almost always lethal, and only about 30% of the women affected will be cured. Thanks to a better understanding of the molecular mechanisms underlying ovarian cancer malignancy, new therapeutic options with molecular-targeted agents have become available. This review discusses the rationale behind molecular-targeted therapies and examines how newly identified molecular targets may enhance personalized therapies for ovarian cancer patients. Keywords: ovarian cancer, angiogenesis, PI3K/Akt, BRCA, metabolism
format	article
author	Sourbier C
author_facet	Sourbier C
author_sort	Sourbier C
title	Ovarian cancer: emerging molecular-targeted therapies
title_short	Ovarian cancer: emerging molecular-targeted therapies
title_full	Ovarian cancer: emerging molecular-targeted therapies
title_fullStr	Ovarian cancer: emerging molecular-targeted therapies
title_full_unstemmed	Ovarian cancer: emerging molecular-targeted therapies
title_sort	ovarian cancer: emerging molecular-targeted therapies
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/dd4a34d48c32494997b7bf50af34c666
work_keys_str_mv	AT sourbierc ovariancanceremergingmoleculartargetedtherapies
_version_	1718404016580329472

Ovarian cancer: emerging molecular-targeted therapies

Ejemplares similares